Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: A prospective pilot study

Current Therapeutic Research - Clinical and Experimental

Volumn 71, Issue 6, 2010, Pages 360-368

  Vlase, Laurian ^a   Neag, Maria ^a   Popa, Adina ^a   Muntean, Dana ^a   Leucuta, Sorin E ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Drug interaction; Fluoxetine; Omeprazole; Pharmacokinetics

Indexed keywords

FLUOXETINE; FLUOXIN; OMEPRAZOLE; OMERAN; UNCLASSIFIED DRUG;

ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BODY MASS; CENTRAL NERVOUS SYSTEM DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INHIBITION; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEARTBURN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INSOMNIA; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NORMAL HUMAN; PILOT STUDY; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; XEROSTOMIA;

EID: 79952085359     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(10)80002-5     Document Type: Article

References (24)

1. Kromer W, Horbach S, Lühmann R Relative efficacies of gastric proton pump inhibitors: Their clinical and pharmacological basis. Pharmacology. 1999, 59:57-77.
2. McTavish D, Buckley MM, Heel RC Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs. 1991, 42:138-170.
3. Cederberg C, Andersson T, Skånberg I Omeprazole: Pharmacokinetics and metabolism in man. Scand J Gastroenterol Suppl. 1989, 166:33-40. discussion.
4. Cederberg C, Andersson T, Skånberg I Omeprazole: Pharmacokinetics and metabolism in man. Scand J Gastroenterol Suppl. 1989, 166:41-42.
5. Andersson T, Cederberg C, Heggelund A, Lundborg P The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40 mg omeprazole as enteric-coated granules. Drug Invest. 1991, 3:45-52.
6. Chiba K, Kobayashi K, Manabe K, et al. Oxidative metabolism of omeprazole in human liver microsomes: Cosegregation with S-mephenytoin 4'-hydroxylation. J Pharmacol Exp Ther. 1993, 266:52-59.
7. Andersson T, Miners JO, Veronese ME, Birkett DJ Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol. 1994, 37:597-604.
8. Andersson T Omeprazole drug interaction studies. Clin Pharmacokinet. 1991, 21:195-212.
9. Altamura AC, Moro AR, Percudani M Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet. 1994, 26:201-214.
10. Baumann P, Rochat B Comparative pharmacokinetics of selective serotonin reuptake inhibitors: A look behind the mirror. Int Clin Psychopharmacol. 1995, (Suppl 1):15-21.
11. Potkin SG, Thyrum PT, Alva G, et al. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol. 2002, 22:174-182. Pharmacokinetic Study Group.
12. Bergstrom RF, Goldberg MJ, Cerimele BJ, Hatcher BL Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clin Pharmacol Ther. 1997, 62:643-651.
13. Guidance for Industry: In vivo drug metabolism/drug interaction studies-study design, data analysis, and recommendations for dosing and labeling US Dept of Health and Human Services, Food and Drug AdministrationFood and Drug Administration, Center for Drug Evaluation and Research (CDER)Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)Center for Biologics Evaluation and Research (CBER), Accessed June 28, 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072119.pdf.
14. Studies for orally administered drug products-general considerations US Dept of Health and Human Services, Food and Drug AdministrationFood and Drug Administration, Center for Drug Evaluation and Research (CDER)Center for Drug Evaluation and Research (CDER), Guidance for IndustryGuidance for Industry, Bioavailability and BioequivalenceBioavailability and Bioequivalence, Accessed June 28, 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf.
15. Note for Guidance on the Investigation of Bioavailability and Bioequivalence The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal ProductsCommittee for Proprietary Medicinal Products, Accessed June 28, 2010. http://www.ema.europa.eu/pdfs/human/qwp/140198en.pdf.
16. Zhang TT, Song M, Hang TJ, et al. Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa). J Clin Pharm Ther. 2009, 34:345-354.
17. Schuirmann DJ A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987, 15:657-680.
18. Tanigawara Y, Aoyama N, Kita T, et al. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther. 1999, 66:528-534.
19. Calabresi L, Pazzucconi F, Ferrara S, et al. Pharmacokinetic interactions between omeprazole/ pantoprazole and clarithromycin in health volunteers. Pharmacol Res. 2004, 49:493-499.
20. Yasui-Furukori N, Takahata T, Nakagami T, et al. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol. 2004, 57:487-494.
21. Kita T, Tanigawara Y, Aoyama N, et al. CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability. Pharm Res. 2001, 18:615-621.
22. Clark DW, Strandell J Myopathy including polymyositis: A likely class adverse effect of proton pump inhibitors?. Eur J Clin Pharmacol. 2006, 62:473-479.
23. Berardi RR, Welage LS Peptic ulcer disease. Pharmacotherapy: A Pathophysiologic Approach 2008, McGraw-Hill Medical, New York, NY. 7th ed. J.T. Dipiro, R.L. Talbert, G.C. Yee (Eds.).
24. Spina E, Scordo MG Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging. 2002, 19:299-320.